No standardised endpoint definitions exist to aid the design of trials that compare antibiotic therapies for bloodstream infection (BSI). We reviewed endpoints used in contemporary BSI studies and defined consensus endpoints using a modified Delphi process. Prospective studies, randomised trials or registered protocols comparing antibiotic therapies for BSI, published from 2005 to 2016, were reviewed. Different primary and secondary endpoints were defined for pilot (small-scale studies designed to evaluate protocol design, feasibility and implementation) and definitive trials (larger-scale studies designed to test hypotheses and influence clinical practice), as well as for Staphylococcus aureus and Gram-negative BSI. For pilot studies of S.
Introduction
Bloodstream infection (BSI) is common and potentially lethal. It has been estimated that nosocomial BSI account for 575,000-677,000 episodes and 79,000-94,000 deaths in the USA [1] . It is a frequent reason for consultation with infectious diseases (ID) physicians and clinical microbiologists [2, 3] . The U.S. Food and Drug Administration (FDA) has not approved a new antibiotic specifically for BSI since daptomycin in 2006. However, there is considerable interest among clinicians and pharmaceutical companies in studying different antibiotic choices for this infection.
Defining clinically meaningful endpoints will lend greater credibility and validity to clinical trials on antibiotic treatment. There are no uniform primary endpoints to compare antibiotic options for BSI. Standardised endpoints would have the advantage of facilitating study comparison and reducing data heterogeneity in meta-analyses, as well as providing guidance to researchers when designing studies. The purpose of this article is to describe consensus BSI endpoint definitions for use in future clinical trials and to delineate further work needed in order to optimise these definitions.
Methods
Twenty-seven researchers from 11 different countries working in the field of clinical infectious diseases, microbiology, critical care medicine or biostatistics/trial design agreed to take part in a modified Delphi process [4] in order to develop consensus endpoint definitions for studies comparing antibiotic treatments for BSI. Six rounds of surveys were sent to each participant, with each round building on the results of previous rounds using a web-based survey tool (www.surveymonkey.com). The details of the Delphi process are summarized in Table 1 . When unanimous agreement amongst participants was not achieved for any particular question, the level of agreement and pertinent comments of the participants were then distributed in the next survey round. In this way, consensus was sought. Agreement was defined by majority support (>60% agree) for each component of the definitions.
Literature review
In order to examine pre-defined endpoints currently used by researchers, we reviewed randomised controlled trials and prospective comparative studies assessing antibiotic treatment for adult patients with BSI caused Gram-negative bacilli or Staphylococcus aureus. We searched PubMed and Scopus for relevant studies using the terms "prospective", "antibiotic" and "bacteremia" limited to clinical trial article types published between January 2005 and April 2016. We included published trial protocols for actively recruiting BSI studies, by searching ClinicalTrials.gov. We excluded retrospective studies, studies where endpoints were not clearly pre-defined, studies that did not compare antibiotic therapies as a primary aim, those involving fungi or Gram-positive organisms other than S. aureus, duplicated studies or those published in languages other than English.
Results
Thirteen different endpoints have been used in contemporary BSI studies. These endpoints are summarized in Table 2 (study details can be found in Supplementary Table 1 ). The panel agreed that no well validated primary endpoints for the study of antibiotics in the treatment of BSI existed (Round 3: 17 agreed, 0 disagreed). The majority of the panel felt that primary endpoints needed to be different for studies of BSI due to S. aureus vs. Gram-negative bacilli (Round 3: 16 agreed, 1 disagreed). This was due to the different spectrum of complications associated with BSI due to Gram-negative bacilli as compared to S. aureus. The majority also felt that endpoints for pilot studies should differ compared to those for large definitive studies (Round 3: 16 agreed, 1 disagreed). The panel agreed that trial endpoints should not be defined by deviation from the trial protocol (Round 4: 18 agreed, 1 disagreed). For example, starting a non-study antibiotic for a secondary infection, or failing to take protocoldefined blood cultures, should not be regarded as clinical failure.
Objective clinical outcomes
The panel agreed that the most objective clinical outcome is mortality, and that it should always be measured as an outcome in trials of antibiotic treatment for BSI.
While mortality as an outcome is clearly objective, differences exist as to when mortality should be measured and whether it should be attributed to the BSI as its primary cause.
The panel considered the optimal timing for measuring this outcome. Once this time point is extended far beyond the initial BSI, mortality may become dominated by underlying disease. Mortality has been variably measured 'in hospital' or following discharge, with the timing of mortality determination occurring at 7, 14, 28-30 or 90 days. Early mortality (e.g. 7-14 days) may be more specific for infection-related mortality, but may fail to capture delayed fatalities that could still be influenced by the BSI event. In the consensus definitions, early mortality (7 days) was used for pilot studies, and later mortality (90 days) for larger, definitive studies (Table 3) .
Despite the objectivity of mortality as an endpoint, the panel did not agree that mortality should be used as the sole primary outcome measure. Mortality as a sole outcome may not capture other clinically relevant effects of different antibiotic regimens. The use of attributable mortality was not recommended given the uncertainty of attributing death to the BSI alone (Round 4: 15 agreed 4 disagreed).
The panel concluded that mortality should be included as part of any primary endpoint, but should be accompanied by clinically relevant secondary endpoints.
Other objective endpoints such as length of stay in hospital or rates of re-admission were considered by the panel, since they may reflect an important consideration from the point of view of a patient or the "payer" of a healthcare system. In critical care medicine, endpoints such as intensive care unit (ICU)-free days alive have been used [5] . There is likely to be a wide variability in length of hospital stay due to patient or clinician preference or institutional practices. In the absence of uniform standards for discharge from hospital following BSI, these outcomes were not included in the consensus primary endpoints.
Subjective clinical outcomes
Health related quality of life is important to patients. Unfortunately, it is difficult to get a reliable measure of pre-antibiotic quality of life since BSI is an unexpected event, although a measure of "functional status" (e.g. the Karnofsky score [6] ) may be more readily determined pre-BSI. The panel concluded that such measures are clearly important for patients, but lack sufficiently robust measurements at the present time to permit their use as primary endpoints, but may be suitable for secondary endpoints.
Several panel members suggested that patient-centred measures should be explored in future research and could be adapted from existing scoring systems. Some commonly used quality of life scores that may be applicable to BSI are summarised (Supplementary Table 2 ).
Resolution of symptoms relevant to the BSI may be considered evidence of "clinical cure". Even when used in conjunction with resolution of signs of abnormality on physical examination or radiologic investigations, some panel members expressed a view that assessment of "clinical cure" was too subjective to be used as a primary endpoint (although may be considered as a secondary endpoint). However, regulatory authorities such as the FDA or European Medicines Agency (EMA) currently recommend such clinical outcome measures, in conjunction with microbiological response, for registration trials of treatment for urinary tract infection [7, 8] . Given that BSI can represent a heterogeneous clinical entity, especially for Gram-negative organisms, including of a measure of subjective clinical response may be useful in comparing efficacy when the BSI may reflect a final common path for different infectious syndromes (e.g. urinary tract infection, pneumonia, catheter-associated infection). When used, standardised criteria should be employed and assessed by a blinded and independent clinical events committee.
Microbiologic endpoints
A potential microbiologic endpoint is clearance from the blood of the pathogen of interest. This has been used as a primary endpoint in a recent pilot study of antibiotic regimens for methicillin-resistant S. aureus (MRSA) BSI [9] , and as a secondary endpoint in a trial evaluating continuous infusion of beta-lactam antibiotics [5] . The panel considered that this endpoint is less relevant for Gram-negative BSI, where prolonged bacteraemia is uncommon [10] and much less frequent than for S. aureus [11] . Breakthrough infections may be of relevance for some Gram-negative BSIs, such as AmpC-hyperproducing variants of Enterobacter cloacae [12] .
The panel agreed that relapse of BSI or recurrence of infection at a distant site was an important endpoint for S. aureus BSI. This endpoint should always be used in conjunction with clinical endpoints. Furthermore, recurrence of infection at a distant site may not always be amenable to microbiological confirmation by culture (e.g. vertebral osteomyelitis), and some panel members expressed a view that this may be better defined as a clinical endpoint. However, given the lack of specificity in determining microbiological failure without culture confirmation, the consensus endpoints require culture of S. aureus from sterile sites to define failure ( Table 3 ).
The optimal duration of follow-up required to capture these events is uncertain.
However, the great majority of cases relapse within 6 weeks of initial BSI [13, 14] .
An additional area of uncertainty is defining the optimal clinical samples to include in the follow-up period to determine microbiological failure. For BSI studies it may be important to discriminate between persistent and relapsed BSI by including stipulation for collection of 'clearance' blood cultures. A protocol that requires frequent additional blood sampling may also suffer from limited adherence and consequent missing data. Furthermore, relapse of infection at distant sites (e.g. bone and joint infection) would need to be captured by also including sterile site specimens. Inclusion of non-sterile samples (e.g. sputum, urine) would be less specific for true microbiological relapse. Appropriate molecular typing methods should be applied to discriminate between re-infection and relapse.
Surrogate endpoints
Surrogate endpoints have been used extensively in clinical trials within other areas of infectious disease (e.g. HIV viral load [15] ). For trials comparing treatment for BSI, investigators could potentially measure response to therapy either by using relevant biomarkers (e.g. C-reactive protein, procalcitonin) or clinical parameters (e.g. an illness severity score).
The panel considered what attributes would constitute a useful surrogate marker in the context of BSI. Practical definitions of a meaningful surrogate marker are available (see Panel 1, supplementary data) [16] . Essentially, a surrogate must capture any relationship between the treatment and the true endpoint of interest. The panel expressed the view that while the use of surrogate outcomes has potential advantages, great care needs to be taken in the selection and validation of the surrogate outcome.
The panel considered the role of measuring resolution of clinical features of infection (e.g. fever, tachycardia, white cell count) as a surrogate endpoint. However, it was agreed that these markers could not be used as a sole primary endpoint, given that so many variables other than antibiotic activity may have an influence. There was interest in using the Sequential Organ Failure Assessment (SOFA) score, which captures information on respiratory, cardiovascular, hepatic, coagulation, renal and neurological systems [17] and can be used to assess daily changes in a patient's status within the ICU. This is an advantage over APACHE [18] or SAPS [19] , which predict mortality based on the first 24 hours of observation. However, SOFA requires measurements that are only generally applicable in ICU, such as arterial blood gas analysis. A modified SOFA score may be more applicable to general ward patients [20] . Other scoring systems of disease severity that may be applicable in BSI studies were discussed and are summarised in Supplementary Table 3 .
The consensus panel universally agreed that no reliable or well-validated surrogate endpoint for mortality currently exists to use in BSI trials (Round 3: agreed 17, disagreed 0). They may have greater applicability in phase II trials or be used as part of secondary outcome measures in phase III trials.
Composite endpoints
Composite endpoints can enhance the power of a clinical trial and capture a wider spectrum of clinically relevant events and increase the expected event rate. However, several members of the panel expressed caution. The frequency of combined events may not occur in the same direction cancelling-out an overall effect. Furthermore, one component of the combined outcome may be more clinically important than another, and significant differences may be driven by less serious outcomes. As such, each component of a composite outcome should be reported separately to assess the direction and size of each effect. If more than one primary endpoint is used, the chance of obtaining a significant result by chance alone is also increased. Appropriate weighting of components of greater significance is essential but the panel could not find examples where they were used in trials of BSI.
The panel considered composite endpoints used or proposed in trials of S. aureus BSI.
The endpoints used in a published randomised controlled trial (RCT) of daptomycin vs. vancomycin for treatment of BSI, which used a primary outcome of clinical success at 42 days (with failure defined by clinical and microbiological factors as well as protocol violations) [21] came under criticism. Concerns included failure defined by starting a non-study antibiotic for a secondary infection, or failing to take protocol blood cultures. The primary endpoints used by the ARREST [22] (co-primary outcome of all-cause mortality up to 14 days from randomisation and bacteriological failure/all-cause mortality up to 12 weeks) or CAMERA [9] (composite primary endpoint at 90 days of all-cause mortality, persistent bacteraemia at day 5 or beyond, microbiological relapse, or microbiological treatment failure) studies were felt to be more appropriate, although consensus could not be reached as to which endpoint was superior.
New composite endpoints for BSI caused by S. aureus and for Gram-negative organisms with a >10% risk of mortality (e.g. E. coli) were determined by consensus (Table 3) Table 4 .
Ordinal Scales
The panel considered the use of a desirability of outcome ranking (DOOR) score as described by Evans and colleagues [23]. Our panel was not able to reach consensus on this topic (Table 1 ) (Round 6: 10 Agree, 9 disagreed). The perceived advantages and disadvantages of a desirability of outcome scale by our panel are summarised in Table 4 .
Discussion

BSI is a common condition encountered by ID physicians and clinical
microbiologists, yet many questions remain as to its optimal management. In a recent survey, ID physicians were asked to rank proposals for RCTs in terms of which were most likely to change their practice. Five of the ten top-ranking RCT proposals were related to BSI due to S. aureus, Enterococcus or multiresistant Gram-negative pathogens [3] . early phase trial may represent a statistical anomaly that fails to translate into a significant effect in later phase trials. It is unlikely that a 'perfect' set of endpoints can be currently defined, but this work can provide a basis for future evidence-based refinement.
In conclusion, we have proposed primary endpoints that could be used in future observational and interventional studies of antibiotics for BSI. It is also hoped that this manuscript will stimulate further research into which endpoints are most likely to enhance antibiotic prescribing practices and improve patient outcomes. Secondary endpoints often assess a range of other clinical outcomes, may be pathogen specific (e.g.
S. aureus)
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